These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
517 related articles for article (PubMed ID: 25395835)
1. Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence. Zalpour A; Oo TH Drug Des Devel Ther; 2014; 8():2181-91. PubMed ID: 25395835 [TBL] [Abstract][Full Text] [Related]
2. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. Cohen AT; Hamilton M; Mitchell SA; Phatak H; Liu X; Bird A; Tushabe D; Batson S PLoS One; 2015; 10(12):e0144856. PubMed ID: 26716830 [TBL] [Abstract][Full Text] [Related]
3. New oral anticoagulants for the treatment of venous thromboembolism. Agnelli G; Becattini C; Franco L Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903 [TBL] [Abstract][Full Text] [Related]
4. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism. Beyer-Westendorf J; Ageno W Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence. Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT Clin Ther; 2016 Mar; 38(3):478-93.e1-16. PubMed ID: 26922297 [TBL] [Abstract][Full Text] [Related]
6. Impact of apixaban vs low molecular weight heparin/vitamin k antagonist on hospital resource use in patients with venous thromboembolism. Browne C; Lanitis T; Hamilton M; Li X; Horbyluk R; Mardekian J; Kongnakorn T; Cohen A J Med Econ; 2017 Jan; 20(1):98-106. PubMed ID: 27822962 [TBL] [Abstract][Full Text] [Related]
7. Long-term benefits of preventing venous thromboembolic events. Cohen AT Curr Med Res Opin; 2012 Jun; 28(6):877-89. PubMed ID: 22533680 [TBL] [Abstract][Full Text] [Related]
9. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials. Ma G; Zhang R; Wu X; Wang D; Ying K Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496 [TBL] [Abstract][Full Text] [Related]
10. Antidotes to non-vitamin K oral anticoagulants: necessary or not? Proietti M; Lip GY Expert Opin Pharmacother; 2015; 16(11):1573-6. PubMed ID: 26077323 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences. Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT BMC Health Serv Res; 2017 Jan; 17(1):74. PubMed ID: 28114939 [TBL] [Abstract][Full Text] [Related]
12. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US. Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M J Med Econ; 2015 Jun; 18(6):399-409. PubMed ID: 25586203 [TBL] [Abstract][Full Text] [Related]
13. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis. Alotaibi G; Alsaleh K; Wu C; Mcmurtry MS Int Angiol; 2014 Aug; 33(4):301-8. PubMed ID: 25056161 [TBL] [Abstract][Full Text] [Related]
14. Venous thromboembolism management: where do novel anticoagulants fit? Spyropoulos AC; Turpie AG Curr Med Res Opin; 2013 Jul; 29(7):783-90. PubMed ID: 23659584 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the Netherlands. de Jong LA; Dvortsin E; Janssen KJ; Postma MJ Clin Ther; 2017 Feb; 39(2):288-302.e4. PubMed ID: 28139289 [TBL] [Abstract][Full Text] [Related]
16. Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery. Quinlan DJ; Eriksson BI Best Pract Res Clin Haematol; 2013 Jun; 26(2):171-82. PubMed ID: 23953905 [TBL] [Abstract][Full Text] [Related]
17. Apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients receiving chemotherapy: Rational and design of the AVERT trial. Kimpton M; Wells PS; Carrier M Thromb Res; 2018 Apr; 164 Suppl 1():S124-S129. PubMed ID: 29703470 [TBL] [Abstract][Full Text] [Related]
18. Emerging anticoagulants for venous thromboembolism prevention. Trujillo TC Am J Health Syst Pharm; 2010 May; 67(10 Suppl 6):S17-25. PubMed ID: 20479087 [TBL] [Abstract][Full Text] [Related]
19. A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention. Revankar N; Patterson J; Kadambi A; Raymond V; El-Hadi W Postgrad Med; 2013 Jul; 125(4):141-53. PubMed ID: 23933902 [TBL] [Abstract][Full Text] [Related]
20. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban. Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]